Details

session_id
sess_SDA-2026-04-11-gap-debate-20260410-111936-9a9b8c46
round_number
4
agent_persona
persona-synthesizer
agent_backend
minimax:MiniMax-M2.7
action
synthesize
tokens_used
622
persona_id
persona-synthesizer
Raw fields (1)
content

```json
{
  "ranked_hypotheses": [
    {
      "rank": 1,
      "hypothesis_id": "H1",
      "title": "TREM2-Dependent Microglial Metabolic Reprogramming as Primary Neuroprotective Mechanism",
      "composite_score": 0.71,
      "dimension_scores": {
        "mechanistic_plausibility": 0.75,
        "evidence_strength": 0.72,
        "novelty": 0.55,
        "feasibility": 0.70,
        "therapeutic_potential": 0.80,
        "druggability": 0.85,
        "safety_profile": 0.55,
        "competitive_landscape": 0.60,
        "data_availability": 0.80,
        "reproducibility": 0.75
      },
      "evidence_for": [
        {"claim": "Human coding variants in TREM2 (R47H) increase AD risk ~3-fold, establishing TREM2 as causal", "pmid": "30327531"},
        {"claim": "TREM2-deficient microglia fail to upregulate lipid metabolism genes and show impaired amyloid compaction", "pmid": "31278165"},
        {"claim": "TREM2+ microglia show trajectory from homeostatic to disease-associated state in early Braak stages", "pmid": "SEA-AD snRNA-seq"},
        {"claim": "Single-cell SLEAP analysis shows enrichment for OXPHOS gene modules preceding lysosomal genes", "pmid": "SEA-AD GSEA"},
        {"claim": "AL002 TREM2 agonist in Phase 2 (INVOKE-2) with Denali BBB shuttle technology", "pmid": "NCT04592874"}
      ],
      "evidence_against": [
        {"claim": "TREM2 deficiency reduced tau-mediated neuronal loss in advanced pathology models, suggesting context-dependent role", "pmid": "31881164"},
        {"claim": "TREM2 signaling in some contexts promotes glycolysis for inflammatory responses, not OXPHOS", "pmid": "32349664"},
        {"claim": "Pseudotime trajectory cannot distinguish causal from correlated expression changes", "pmid": "computational limitation"},
        {"claim": "Metabolic reprogramming interpretation ambiguous - OXPHOS could represent compensation rather than proactive protection", "pmid": "theoretical"}
      ],
      "synthesis_notes": "TREM2 remains strongest candidate despite skeptic's valid concerns about stage-dependency. AL002 Phase 2 data will be critical discriminator. Recommended focus on early-stage patient stratification."
    },
    {
      "rank": 2,
      "hypothesis_id": "H3",
      "title": "C9orf72 Haploinsufficiency Disrupts Microglial-Lymphocyte Cross-Talk",
      "composite_score": 0.64,
      "dimension_scores": {
        "mechanistic_plausibility": 0.65,
        "evidence_strength": 0.60,
        "novelty": 0

Voting as anonymous. Sign in to attribute your signals.

tokens

Replication

No replications yet

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.